Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

Novartis International AG / Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Presentation of results from the Kisqali^® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer 

• New MONALEESA-2 analyses focused on quality of life, biomarkers and treatment sequencing to be presented
   

Data across portfolio and pipeline address potential of biomarkers and combination treatments in the neoadjuvant and in the advanced first-line and second-line setting

Basel, November 14, 2017 - Novartis will present data across its breast cancer portfolio and pipeline in a broad range of patient populations, treatment combinations and pathways at the upcoming 40^th annual San Antonio Breast Cancer Symposium (SABCS), San Antonio, December 5-9.

"Our presentations at SABCS will address some of the most pressing challenges and questions facing the advanced breast cancer community, including the need to better understand treatment sequencing and biomarkers," said Bruno Strigini, CEO, Novartis Oncology. "At Novartis, we seek to advance scientific understanding of breast cancer with the ultimate goal of improving treatments and outcomes for those affected by the disease. We are pleased to share the latest data from our MONALEESA program, which continues to evaluate the potential of Kisqali treatment in new patient populations."

Results from the Phase III MONALEESA-7 trial in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented for the first time in a late-breaker oral presentation.

• First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial [Abstract #S2-05; Wednesday, December 6, 4:15 - 4:30 PM CST]

Additional abstracts from across the breast cancer portfolio include: